SLGL - Sol-Gel Technologies Ltd.
| Previous close | 8.68 |
| Open | 8.13 |
| Bid | 7.95 x 1300 |
| Ask | 8.80 x 1000 |
| Day's range | 8.13 - 8.58 |
| 52-week range | 5.41 - 11.36 |
| Volume | 1,046 |
| Avg. volume | 22,989 |
| Market cap | 174.98M |
| Beta (3Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.75 |
| Earnings date | 13 Aug 2019 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 19.20 |
- Simply Wall St.
Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 40% Discount?
Does the September share price for Sol-Gel Technologies Ltd. (NASDAQ:SLGL) reflect what it's really worth? Today, we...
- Zacks
Sol-Gel Technologies Ltd. (SLGL) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Sol-Gel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Investors Who Bought Sol-Gel Technologies (NASDAQ:SLGL) Shares A Year Ago Are Now Up 49%
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick...
- MarketWatch
UPDATE: Sol-Gel Technologies shares soar 9.5% on news of positive results in trials of rosacea treatment
Sol-Gel Technologies Ltd. shares soared 9.5% in premarket trade Monday, after the company said that two late-stage trials of a treatment for papulopustular rosacea produced positive results. The Israeli company said the trials evaluating Epsolay(R) microencapsulated benzoyl peroxide cream, 5%, made with the company's proprietary microencapsulation technology, met its main goals. Epsolay showed statistically significant improvement in both primary endpoints of the number of patients achjieving "clear" or "almost clear" in the Investigator Global Assessment (IGA) and absolute mean reduction from baseline in inflammatory lesion count, the company said in a statement. Papulopustular rosacea is a chronic inflammatory skin disorder that affects nearly 5 million Americans. Symptoms include redness on the cheeks, nose, chin or forehead and over time, it can cause pimples, burning, stinging, dry skin, plagues and skin thickening. Shares have gained 51.5% in 2019, while the S&P 500 has gained 19.3%.
- Zacks
Analysts Estimate Sol-Gel Technologies Ltd. (SLGL) to Report a Decline in Earnings: What to Look Out for
Sol-Gel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Supernus' ADHD Candidate Positive in 4th Phase III Study
Supernus (SUPN) releases top-line results from the fourth phase III study on SPN-812 for the treatment of attention deficit hyperactivity disorder.
- Zacks
Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects
Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects
- Simply Wall St.
What Percentage Of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Shares Do Insiders Own?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The big shareholder groups in Sol-Gel Technologies Read More...
- Simply Wall St.
Who Has Been Buying Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...
- Simply Wall St.
How Financially Strong Is Sol-Gel Technologies Ltd (NASDAQ:SLGL)?
The direct benefit for Sol-Gel Technologies Ltd (NASDAQ:SLGL), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-offRead More...
